United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund Acquires 63,284 Shares of Edwards Lifesciences Corporation $EW

United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund boosted its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 16.9% in the 2nd quarter, Holdings Channel.com reports. The firm owned 437,403 shares of the medical research company’s stock after purchasing an additional 63,284 shares during the quarter. United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund’s holdings in Edwards Lifesciences were worth $34,209,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in EW. Vanguard Group Inc. lifted its holdings in shares of Edwards Lifesciences by 1.2% during the second quarter. Vanguard Group Inc. now owns 69,997,629 shares of the medical research company’s stock worth $5,474,515,000 after buying an additional 798,801 shares during the last quarter. Geode Capital Management LLC increased its position in Edwards Lifesciences by 0.4% during the second quarter. Geode Capital Management LLC now owns 12,722,416 shares of the medical research company’s stock worth $990,074,000 after acquiring an additional 45,555 shares during the period. Jennison Associates LLC increased its position in Edwards Lifesciences by 15.7% during the second quarter. Jennison Associates LLC now owns 11,670,991 shares of the medical research company’s stock worth $912,788,000 after acquiring an additional 1,584,958 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Edwards Lifesciences by 4.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,783,568 shares of the medical research company’s stock valued at $491,673,000 after purchasing an additional 264,311 shares during the last quarter. Finally, Nuveen LLC bought a new stake in Edwards Lifesciences in the 1st quarter valued at $330,881,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on EW shares. Mizuho boosted their price objective on shares of Edwards Lifesciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a report on Friday, October 31st. Raymond James Financial upgraded Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 price target on the stock in a research note on Monday, November 3rd. Robert W. Baird set a $83.00 price target on Edwards Lifesciences in a report on Friday, October 31st. UBS Group reiterated a “neutral” rating and issued a $90.00 price objective on shares of Edwards Lifesciences in a research report on Monday, November 3rd. Finally, BTIG Research restated a “buy” rating and set a $100.00 price objective on shares of Edwards Lifesciences in a research report on Tuesday. Three analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $91.39.

Edwards Lifesciences Stock Down 0.0%

Shares of EW opened at $86.78 on Thursday. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. The company has a 50-day moving average price of $79.44 and a two-hundred day moving average price of $78.31. The stock has a market cap of $50.36 billion, a price-to-earnings ratio of 12.49, a P/E/G ratio of 3.97 and a beta of 1.03. Edwards Lifesciences Corporation has a 12 month low of $65.94 and a 12 month high of $87.40.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.59 by $0.08. The business had revenue of $1.55 billion during the quarter, compared to analysts’ expectations of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.Edwards Lifesciences’s quarterly revenue was up 14.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. Equities analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 13,000 shares of the stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $83.08, for a total transaction of $1,080,040.00. Following the completion of the sale, the chief financial officer owned 39,898 shares in the company, valued at $3,314,725.84. This trade represents a 24.58% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Daniel J. Lippis sold 1,020 shares of Edwards Lifesciences stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $82.55, for a total transaction of $84,201.00. Following the transaction, the vice president directly owned 22,002 shares of the company’s stock, valued at $1,816,265.10. This represents a 4.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.